Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visualizing VEGF-producing lesions in Von Hippel-Lindau disease with 89Zr-bevacizumab PET
2009-011479-62Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in von Hippel–Lindau disease (VHL), sponsored by University Medical Center Groningen. Primary endpoint: Detection rate of VHL-associated lesions with 89Zr-bevacizumab PET. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on 2009-011479-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011479-62.